October 2026
Welcome Ana Catarina Pacheco
Welcome to Ana Catarina Pacheco, who joined the laboratory as a Postdoctoral Research Fellow.
Engineering drug delivery systems,
from soft matter to clinical translation.
We design drug delivery systems at the interface of soft matter engineering, nanomedicine, and oncology translation.
01 / News
What’s new.
October 2026
Welcome Juliette Seghesio and Louise Chollet
Welcome to Juliette Seghesio and Louise Chollet, who joined the laboratory as PhD students.
July 2026
Advanced Materials Perspective on dual-mechanism antibody–drug conjugates
Congratulations to Xavier Pivot and Sebastian Jung for their latest Perspective in Advanced Materials, “From payload-first toward dual-mechanism antibody–drug conjugates”.
June 2026
ERC Proof of Concept awarded to Alexandre Detappe for Nano-BITE
Alexandre Detappe has been awarded an ERC Proof of Concept grant for Nano-BITE, a multispecific theranostic nano-engager platform.
June 2026
Nature Medicine Perspective on the next generation of antibody-drug conjugates
Fernanda Mosele and colleagues published a new Perspective in Nature Medicine on the next generation of antibody-drug conjugates.
June 2026
New Advanced Drug Delivery Reviews article led by Mainak Banerjee
Congratulations to Mainak Banerjee for leading this review article in Advanced Drug Delivery Reviews on targeted delivery strategies for PROTACs and molecular glue degraders.
June 2026
Guillaume Jacquot completes his PhD
Congratulations to Guillaume Jacquot for completing his PhD on hydrogel-based strategies for the controlled delivery of proteins.
April 2026
Launch of the PEPR BBTI Mono-CHEM project
The laboratory coordinates the PEPR BBTI Mono-CHEM project, in collaboration with the teams of Jean-Luc Perfettini, Suman Mitra, Véronique Decot, Benoit Favier and Eric Olmos, to develop a new cell therapy approach.
December 2025
ACS Nano publication on E3-K3 radioenhancers
Sebastian Jung and colleagues published a new application of the self-assembling E3-K3 peptide platform in ACS Nano, highlighting its potential as a modular radioenhancer system.
02 / Science
How it gets in.
We engineer drug delivery around the route of administration. Each route presents a different biological and physical barrier, and each calls for a different formulation strategy.
Antibodies and ADCs
Subcutaneous
We design injectable biomaterials that confine biologics at the administration site, support high-concentration dosing and control release into the systemic circulation. The same strategy is being extended from monoclonal antibodies to antibody-drug conjugates.
Nanoparticles and prodrugs
Intravenous
We build modular nanocarriers and prodrug architectures whose surface chemistry and payload can be tuned independently. Peptide-mediated ligand display, polymeric prodrugs and liposomal systems provide complementary ways to control targeting, exposure and therapeutic function.
Biologics
Oral
We explore formulations that protect biologics through the gastrointestinal tract and enable local activity at the intestinal interface. Current work includes vesicular systems designed to carry intact monoclonal antibodies to the gut.
Design principles
What carries across.
Across routes and therapeutic classes, four design principles shape how we build delivery systems.
Modular surface engineering
Supramolecular and covalent strategies let us control how ligands are displayed on nanoparticles, polymers and cells, while keeping the carrier architecture adaptable.
Confinement and release
Hydrogels and soft materials are used to control local retention, protein concentration and release kinetics, with formulation properties matched to the molecule being delivered.
Payload-carrier co-design
The carrier is selected and engineered around the constraints of the therapeutic payload, whether the goal is to protect a biologic, deliver a degrader or enhance radiation response.
Quantitative imaging
PET, MRI, fluorescence and spatial readouts are used to connect formulation properties with biodistribution, target engagement and treatment response.
03 / Team
Team.
A multidisciplinary team of biologists, chemists, physicists, pharmacists and physicians working across Strasbourg and Villejuif.
Detappe Lab
Permanent staff
Alumni
Former PhD students
- Guillaume Jacquot
- Vincent Mittelheisser
- Manon Courseyre
Former postdoctoral fellows
- Eric Moeglin
- Chloé Guilbaud-Chéreau
- Chen Zhu
- Clélia Mathieu
- Gamze Tari
Join the laboratory
We welcome applications from PhD candidates and postdoctoral fellows interested in drug delivery, biomaterials, nanomedicine and translational oncology. For enquiries, send a CV and a brief description of your research interests to alexandre.detappe@gustaveroussy.fr.
04 / Contact
Contact.
© OpenStreetMap
alexandre.detappe@gustaveroussy.fr | a.detappe@institut-strauss.fr